ADC & cancer drugs stocks
ADC·항암제
What are ADC & cancer drugs stocks in Korea?
The ADC & cancer drugs theme on jonbur groups 11 Korean stocks listed on KOSPI and KOSDAQ, worth ₩95T in total. On Oct 28, 2026 the group moved up 0.45% (weighted by market value); the largest members are Samsung Biologics, Alteogen, Yuhan.
Key facts
- Stocks
- 11
- Total market value
- ₩95T
- Day's move
- +0.45%
- As of
- Oct 28, 2026
- Largest members
- Samsung Biologics, Alteogen, Yuhan
Earnings tracker · 4Q 2025
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Mar 12 | ₩309B | −75.4% | ₩378B | +16.1% | −48.1% | 122.5%25.9% |
| Alteogen | Mar 23 | ₩65B | +26.9% | ₩20B | −14.7% | −26.4% | 30.4%45.3% |
| Yuhan | Mar 12 | ₩546B | +10.1% | ₩26B | Turned to profit | +18.5% | 4.8%−2.4% |
| Hanmi Pharm | Mar 20 | ₩433B | +23.1% | ₩83B | +173.4% | +51.2% | 19.2%8.7% |
| LigaChem Biosciences | Mar 23 | ₩16B | −52.6% | −₩73B | Bigger loss | Bigger loss | −458.4%−40.7% |
| ABL Bio | Mar 12 | ₩0 | −100.0% | −₩30B | Bigger loss | Bigger loss | — |
| GI Innovation | Mar 18 | ₩5.5B | Turned to profit | −₩7.2B | Smaller loss | Smaller loss | −130.7% |
| ImmuneOncia Therapeutics | Mar 18 | ₩0 | — | −₩9.6B | — | Smaller loss | — |
| Y-Biologics | Mar 23 | ₩449M | −60.9% | −₩3B | Bigger loss | Bigger loss | −665.5%−205.9% |
| Oncocross | Mar 19 | ₩141M | −78.5% | −₩2.2B | Smaller loss | Smaller loss | −1,567.1%−362.1% |
| Eutilex | Mar 19 | ₩2.4B | −9.4% | −₩5B | Smaller loss | Bigger loss | −210.5%−288.9% |
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 28, 2026- Above 20-day average
- 20%
- Above 60-day average
- 10%
- RSI above 70
- 0%
- RSI below 30
- 0%
- 52-week highs
- 0
- 52-week lows
- 0
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The ADC and cancer drugs group comprises 10 members, and 20 of the counted readings show shares above their 20-day averages while 10 sit above their 60-day averages, which leaves the breadth picture split between short-term and medium-term trends. None of the members registered an RSI extreme on either side, and no member recorded a 52-week high or low in the data provided. The equal-weighted member index is labeled bearish on both the short and medium horizons, with its RSI at 41.6 and its price sitting below the cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
Creators talking about this
ADC & cancer drugs
+0.55%ADC·항암제
ADC & cancer drugs is a Korean stock-market theme covering antibody-drug conjugates, which link an antibody to a cytotoxic payload to target cancer cells, along with other oncology drug developers and related contract manufacturing and platform technologies. Korean investors tend to group these companies together because the sector is closely tied to biopharma licensing deals with global pharmaceutical firms and to the technology transfer and manufacturing capacity that supports them. Stocks in this theme often move together on news about clinical trial results, international partnerships, or regulatory milestones.
11 companies · 7 up · 1 flat · 3 down
- Traded value
- ₩221B
- Value vs 20-day average
- 0.76×
- Top gainer
- Hanmi Pharm +5.42%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,372,000 | −0.15% | ₩69B | ₩64T | 6.88% |
Alteogen196170 · KOSDAQ | ₩223,000 | +2.06% | ₩53B | ₩16T | 2.68% |
Yuhan000100 · KOSPI | ₩77,300 | −3.38% | ₩27B | ₩5.7T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩369,500 | +5.42% | ₩42B | ₩4.7T | 9.61% |
LigaChem Biosciences141080 · KOSDAQ | ₩66,200 | +3.60% | ₩13B | ₩2.5T | 4.99% |
ABL Bio298380 · KOSDAQ | ₩41,800 | +2.33% | ₩13B | ₩2.3T | 4.02% |
GI Innovation358570 · KOSDAQ | ₩7,140 | +1.56% | ₩1.3B | ₩461B | 4.07% |
ImmuneOncia Therapeutics424870 · KOSDAQ | ₩2,870 | +1.41% | ₩1.1B | ₩262B | — |
Y-Biologics338840 · KOSDAQ | ₩9,390 | −7.94% | ₩890M | ₩145B | 0.17% |
Oncocross382150 · KOSDAQ | ₩3,145 | +1.13% | ₩64M | ₩41B | — |
Eutilex263050 · KOSDAQ | ₩959 | 0.00% | ₩0 | ₩35B | 0.74% |
Source: KRX statistical information